The top seven challenges in structuring China-related transactions

Apr 23, 2015 Tags: Biotech Deals Investment

China is full of contradictions, as is any transaction involving China. Whether you look at China as a source of capital or as a market, whether your are a Chinese company reaching out globally or an international company negotiating with a Chinese counterpart, the China factor looms large in your strategic planning and implementation. Experts with significant cross-border transaction experience share the top seven challenges they have faced in China. 

Speaker: Peter Corne, LLM – Dorsey & Whitney LLP

Speaker: Frank S. Hong, JD –  Dorsey & Whitney LLP